Sterling Pharma Solutions has acquired Alcami’s Germantown, Wisconsin facility in the US.
The Germantown facility houses cGMP development, scale-up and manufacturing facilities and has specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.
The acquisition follows growth over the past four years, which has seen Sterling invest $46m into its service offering, including a recent $1.5m investment into the company’s Cary facility in the US.
Commenting on the announcement, Kevin Cook, CEO of Sterling Pharma Solutions, said: “We’re delighted to announce our acquisition of the Germantown facility in the US. This is the latest step of our strategic growth plans and will ensure we continue to provide a strong transatlantic API presence to support our customers.
“The US market continues to be a key growth area for us. In addition to bolstering our API clinical and commercial manufacturing the Germantown facility has extensive expertise in handling high potency APIs, which will be a valuable addition to our organisation. We’re excited to welcome the Germantown team into the Sterling family.”
Walt Kaczmarek, CEO of Alcami said: “We want to thank the Germantown leadership team and employees for their dedication to the business and wish them success in the future.
“Alcami has over 40 years of experience providing comprehensive drug product manufacturing and analytical testing services. This transaction continues our strategy to focus investments on our core service offerings.”
This announcement follows several expansion projects, including Alcami’s buildout of the sterile manufacturing site in Charleston, SC and the TriPharm acquisition completed in January 2020. Alcami is adding substantial sterile manufacturing and laboratory capacity with best-in-class facility and equipment design.
